Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Clinical Cancer Research

• Publication date

  2013-10-02

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-13-0152PMID 24088734PMCID PMC4045641
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.

  2013influential reference
• ERCC1 and RRM1: ready for prime time?

  2013cited by this paper
• Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas.

  2013cited by this paper
• Comparing ERCC1 protein expression, mRNA levels, and genotype in squamous cell carcinomas of the head and neck treated with concurrent chemoradiation stratified by HPV status

  2012cited by this paper
• Expression of p16, ERCC1, and EGFR amplification as predictors of responsiveness of locally advanced squamous cell carcinomas of head and neck (SCCHN) to cisplatin, radiotherapy, and erlotinib: A phase II randomized trial.

  2012cited by this paper
• Automated ERCC1 Immunohistochemistry in Non-small Cell Lung Cancer: Comparison of anti-ERCC1 Antibodies 8F1, D-10, and FL-297

  2011cited by this paper
• XPF Expression Correlates with Clinical Outcome in Squamous Cell Carcinoma of the Head and Neck

  2011cited by this paper
• DNA Repair Biomarker Profiling of Head and Neck Cancer: Ku80 Expression Predicts Locoregional Failure and Death following Radiotherapy

  2011cited by this paper
• Validation of ERCC1-XPF immunodetection--letter.

  2010cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• Quantitative, fluorescence-based in-situ assessment of protein expression.

  2009cited by this paper
• Prognostic significance of HPV and p16 status in patients with oropharyngeal cancer treated on a large international phase III trial.

  2009cited by this paper
• The XPA-binding domain of ERCC1 Is Required for Nucleotide Excision Repair but Not Other DNA Repair Pathways*

  2009cited by this paper
• Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma

  2009cited by this paper
• Development of an Unsupervised Pixel-based Clustering Algorithm for Compartmentalization of Immunohistochemical Expression Using Automated QUantitative Analysis

  2009cited by this paper
• Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemoradiotherapy in patients with inoperable non-nasopharyngeal carcinoma of the head and neck.

  2009cited by this paper
• XPF-ERCC1 Participates in the Fanconi Anemia Pathway of Cross-Link Repair

  2009cited by this paper
• Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue.

  2009cited by this paper
• ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer.

  2008cited by this paper
• ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation

  2008cited by this paper
• ERCC1-XPF Endonuclease Facilitates DNA Double-Strand Break Repair

  2008cited by this paper
• Use of systematic analysis of DNA repair pathways in head and neck cancer (HNC) to identify XPF as a novel predictor of induction response, and pMK2 relationship to chemoradiotherapy

  2008cited by this paper
• Platinum-based chemotherapy plus cetuximab in head and neck cancer.

  2008cited by this paper
• Patients with ERCC1-Negative Locally Advanced Esophageal Cancers May Benefit from Preoperative Chemoradiotherapy

  2008cited by this paper
• ERCC1 and non-small-cell lung cancer.

  2007cited by this paper
• Excision Repair Cross Complementation Group 1 Immunohistochemical Expression Predicts Objective Response and Cancer-Specific Survival in Patients Treated by Cisplatin-Based Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

  2007influential reference
• DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.

  2007cited by this paper
• ERCC1 and non-small-cell lung cancer [8]

  2007cited by this paper
• CART: Stata module to perform Classification And Regression Tree analysis

  2006cited by this paper
• DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

  2006cited by this paper
• ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.

  2006cited by this paper
• Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis.

  2005cited by this paper
• Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.

  2005cited by this paper
• Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.

  2004cited by this paper
• Prognostic Significance of p16 Protein Levels in Oropharyngeal Squamous Cell Cancer

  2004cited by this paper
• Habitual Risk Factors for Head and Neck Cancer

  2004cited by this paper
• Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study.

  2003cited by this paper
• Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

  2001cited by this paper
• Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data

  2000cited by this paper
• Action of DNA repair endonuclease ERCC1/XPF in living cells.

  1999influential reference
• Reconstitution of Human Excision Nuclease with Recombinant XPF-ERCC1 Complex*

  1997cited by this paper
• ERCC1/ERCC4 5'-endonuclease activity as a determinant of hypoxic cell radiosensitivity.

  1996cited by this paper
• Roles of XPG and XPF/ERCC1 endonucleases in UV-induced immunostaining of PCNA in fibroblasts.

  1996cited by this paper
• The importance of the ERCC1/ERCC4[XPF] complex for hypoxic-cell radioresistance does not appear to derive from its participation in the nucleotide excision repair pathway.

  1996cited by this paper
• Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.

  1994cited by this paper
• Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3.

  1993cited by this paper
• Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.

  1992cited by this paper
• Biomarkers of aging: do we know what to look for?

  1990cited by this paper
• Cancer statistics

  1989cited by this paper

• DNA repair mechanisms and their therapeutic implications in oral cancer

  2025cites this paper
• Discovery of novel thymidylate synthase (TS) inhibitors that influence cancer angiogenesis and metabolic reprogramming in NSCLC cells.

  2023cites this paper
• Treatment failure shortcomings, possible causes and upcoming phyto-optimism in oral cancer

  2023cites this paper
• Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology.

  2022cites this paper
• Application of Immunohistochemistry in Basic and Clinical Studies.

  2020cites this paper
• Could excision repair cross‐complementing group‐1 mRNA expression from peripheral blood lymphocytes predict locoregional failure with cisplatin chemoradiation for locally advanced laryngeal cancer?

  2020cites this paper
• Survivin expression and impact on head and neck cancer outcomes.

  2020cites this paper
• Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck

  2019cites this paper
• RPL22L1 induction in colorectal cancer is associated with poor prognosis and 5-FU resistance

  2019cites this paper
• Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of ERCC1: SWOG S1201.

  2019cites this paper
• Precision Therapy of Head and Neck Squamous Cell Carcinoma

  2018cites this paper
• Pretreatment direct bilirubin and total cholesterol are significant predictors of overall survival in advanced non‐small‐cell lung cancer patients with EGFR mutations

  2017cites this paper
• Defining the boundaries and expanding the utility of head and neck cancer patient derived xenografts.

  2017cites this paper
• The age-related expression decline of ERCC1 and XPF for forensic age estimation: A preliminary study.

  2017cites this paper
• Prognostic implication of ERCC1 protein expression in resected oropharynx and oral cavity cancer.

  2017cites this paper
• Survivin as a Therapeutic Target in Squamous Cell Carcinoma

  2017cites this paper
• EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer

  2016cites this paper
• Identification of evolutionarily conserved DNA damage response genes that alter sensitivity to cisplatin

  2016cites this paper
• Nucleotide Excision Repair and head and neck cancers.

  2016influential citation
• Biomarkers for Individualized Oral Cancer Therapy

  2015cites this paper
• Xenograft assessment of predictive biomarkers for standard head and neck cancer therapies

  2015cites this paper
• Phospho-T356RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neck

  2015cites this paper
• Expression of ERCC1 and TUBB3 in Locally Advanced Cervical Squamous Cell Cancer and its Correlation with Different Therapeutic Regimens

  2015cites this paper
• HPV-negative head and neck squamous cell carcinomas: how can we use the tumor protein signature?

  2015cites this paper
• DNA Damage Proteins and Response to Therapy in Head and Neck Cancer

  2014cites this paper
• Die Tumorbiologie von Kopf-Hals-Tumoren

  2014cites this paper
• Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303

  2014cites this paper